Administration of Recombinant Activated Factor VII (NovoSeven) in Three Cases of Uncontrolled Bleeding Caused by Disseminated Intravascular Coagulopathy

Off-Label Use of Recombinant Activated Factor VII (NovoSeven®)

NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)

UNLABELLED This case report presents a newly diagnosed congenital factor VII deficiency treated with recombinant activated factor VII (rFVIIa). Congenital factor VII deficiency is a rare autosomal-recessive bleeding disorder that occurs in fewer than 1/500,000 persons. Its presentation can vary from epistaxis to hemarthroses and severe central nervous system bleeding, and correlates poorly with...

Special report: recombinant activated factor VII for uncontrolled bleeding in non-hemophiliac patients.

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)

Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...

An Evaluation of Off-Label Use of Recombinant Activated Human Factor VII (NovoSeven)

INTRODUCTION Recombinant activated coagulation factor VII (rFVIIa) is a hemostatic agent developed by Novo Nordisk Pharmaceuticals, Inc., under the trademark NovoSeven. It is a recombinant DNA preparation of a naturally occurring protease, activated blood coagulation factor VII. It is nearly identical to plasmaderived activated factor VII in its pharmacokinetics, structure, and function. The FD...